Inflammatix, Inc

About this entry

Inflammatix will bring to market a gold standard diagnostic for sepsis based on our unique immune biomarkers, enabling precision medicine for acute infectious disease.

HostDx Fever has been shown to accurately separate bacterial and viral infections across dozens of cohorts from all around the world. Our cheap, rapid, PCR-based assay will be available at low cost in convenient sample-to-answer format. By accurately identifying which patients have bacterial, as opposed to viral, acute infections, we should be able to better adjudicate which patients will benefit from antibiotics, reducing overprescription and identifying occasionally missed bacterial infections. 

If you would like to be introduced to this team for collaboration, get in touch with the Longitude prize.